RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Prothena Corporation Stock

Prothena Corporation Stocks 2024

Prothena Corporation Stocks

53.22 M

Ticker

PRTA

ISIN

IE00B91XRN20

WKN

A1KAVV

In 2024, Prothena Corporation had 53.22 M outstanding stocks, a 0% change from the 53.22 M stocks in the previous year.

The Prothena Corporation Stocks history

YEARNUMBER OF STOCKS (undefined USD)
2029e53.22
2028e53.22
2027e53.22
2026e53.22
2025e53.22
2024e53.22
202353.22
202247.4
202148.5
202039.9
201939.9
201839.6
201737.7
201634.4
201530.3
201424.7
201318.6
201214.6
201114.5
201014.5
200914.5

Prothena Corporation shares outstanding

The number of shares was Prothena Corporation in 2023 — This indicates how many shares 53.216 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Prothena Corporation earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Prothena Corporation's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Prothena Corporation’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Prothena Corporation's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Prothena Corporation Aktienanalyse

What does Prothena Corporation do?

Prothena Corporation PLC is a biopharmaceutical company based in Dublin, Ireland, specializing in the development of therapies for protein diseases. The company was spun off from Elan Corporation's research department in 2012 and has been listed on NASDAQ since 2014. Prothena's business model is based on the discovery and development of novel therapeutic approaches for neurodegenerative diseases and cancer caused by misfolded proteins. The company leverages its expertise in protein biochemistry and physics to identify targeted drug candidates that can modulate specific protein structures and their functions. Prothena's key focus areas include researching antibodies against amyloid-beta plaques, which accumulate in the brain in Alzheimer's disease, and developing molecules that can inhibit the disease-causing protein alpha-synuclein in Parkinson's patients. Additionally, the company is working on therapies for ATTR (amyloidosis) and AL amyloidosis. A major success for Prothena was the development of NEOD001, a humanized antibody that targets the amyloid fibril protein (AL) deposited in AL amyloidosis. The drug demonstrated significant efficacy in clinical trials and improved patients' quality of life. Prothena licensed NEOD001 to Pfizer in 2017. Another important product from Prothena is PRX002, a monoclonal antibody specifically targeting the alpha-synuclein protein and inhibiting its spread in the brain. PRX002 is currently undergoing clinical trials for the treatment of Parkinson's patients and is considered a promising medication. Prothena collaborates closely with research partners and other pharmaceutical companies such as Roche/Genentech and Celgene to advance their research activities and the development of new therapeutics. The company has strong regulatory expertise and aims to obtain approvals for new therapies to provide improved quality of life for patients with rare or serious diseases. Overall, Prothena is a leading company in the field of protein biochemistry and the development of innovative therapies for protein diseases. With a strong research pipeline and a wide range of product candidates, the company has the potential to improve the lives of millions of people suffering from serious illnesses. Prothena Corporation ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Stocks Details

Evaluating Prothena Corporation's Shares Outstanding

Prothena Corporation's shares outstanding refer to the total number of shares that are currently held by all its shareholders, including institutional investors and restricted shares held by the company’s officers and insiders. The number of shares outstanding is crucial in determining the company's market capitalization and is used by investors to assess the company’s size, financial health, and investment potential.

Year-to-Year Comparison

Tracking the changes in Prothena Corporation’s shares outstanding over the years can provide investors with insights into the company's financial strategies and market valuation. An increase in shares outstanding can result from actions like issuing new shares, while a decrease can result from buybacks.

Impact on Investments

For investors, understanding Prothena Corporation’s shares outstanding is essential for evaluating its earnings per share (EPS) and market valuation. A change in the number of shares outstanding can impact the EPS, which is a significant driver of stock prices and investor decisions.

Interpreting Changes in Shares Outstanding

Variances in Prothena Corporation’s shares outstanding can signal shifts in the company’s financial strategy. An increase may dilute the EPS and share value, indicating potential fundraising or acquisitions. Conversely, a decrease, often due to share buybacks, can enhance share value and indicate the company’s confidence in its financial performance.

Frequently Asked Questions about Prothena Corporation stock

How many stocks are there of Prothena Corporation?

The current number of stocks of Prothena Corporation is 53.22 M undefined.

What does Number of Shares / OutstandingShares mean?

The outstanding shares (or issued shares) of Prothena Corporation are the total number of shares issued and actively held by shareholders - both external investors and company insiders. However, these must be actual shares. may grant stock options to executives that can be converted into shares.

How has the number of shares of Prothena Corporation evolved in recent years?

The number of shares of Prothena Corporation has increased by 0% gestiegen compared to last year.

What does the number of shares mean for investors?

The number of shares outstanding is used to calculate key metrics such as a company's market capitalization, earnings per share (EPS), and cash flow per share (CFPS). The number of outstanding shares of a company is not static and can fluctuate greatly over time.

Why does the number of stocks fluctuate?

There are various factors that can lead to a change. Prothena Corporation as a company can issue new shares, carry out stock splits or reverse splits.

Does the number of shares have an impact on the performance of Prothena Corporation?

There is no tangible long-term evidence or study that stocks with a certain number of shares (regardless of Mega/Large/Mid/Small Cap) would yield significantly higher returns than others. There are occasional small studies (limited number of stocks, short investment period) that certain classes outperform or have higher risk, but none of them are 1. conclusive (cause-effect is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).

How much dividend does Prothena Corporation pay?

Over the past 12 months, Prothena Corporation paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Prothena Corporation is expected to pay a dividend of 0 USD.

What is the dividend yield of Prothena Corporation?

The current dividend yield of Prothena Corporation is .

When does Prothena Corporation pay dividends?

Prothena Corporation pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Prothena Corporation?

Prothena Corporation paid dividends every year for the past 0 years.

What is the dividend of Prothena Corporation?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Prothena Corporation located?

Prothena Corporation is assigned to the 'Health' sector.

Wann musste ich die Aktien von Prothena Corporation kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Prothena Corporation from 10/21/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/21/2024.

When did Prothena Corporation pay the last dividend?

The last dividend was paid out on 10/21/2024.

What was the dividend of Prothena Corporation in the year 2023?

In the year 2023, Prothena Corporation distributed 0 USD as dividends.

In which currency does Prothena Corporation pay out the dividend?

The dividends of Prothena Corporation are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Prothena Corporation

Our stock analysis for Prothena Corporation Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Prothena Corporation Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.